Literature DB >> 31826876

MAIT Cells Promote Tumor Initiation, Growth, and Metastases via Tumor MR1.

Juming Yan1,2, Stacey Allen1, Elizabeth McDonald1, Indrajit Das3, Jeffrey Y W Mak4,5, Ligong Liu4,5, David P Fairlie4,5, Bronwyn S Meehan6, Zhenjun Chen6, Alexandra J Corbett6, Antiopi Varelias2,7, Mark J Smyth2,3, Michele W L Teng8,2.   

Abstract

Mucosal-associated invariant T (MAIT) cells are innate-like T cells that require MHC class I-related protein 1 (MR1) for their development. The role of MAIT cells in cancer is unclear, and to date no study has evaluated these cells in vivo in this context. Here, we demonstrated that tumor initiation, growth, and experimental lung metastasis were significantly reduced in Mr1 -/- mice, compared with wild-type mice. The antitumor activity observed in Mr1 -/- mice required natural killer (NK) and/or CD8+ T cells and IFNγ. Adoptive transfer of MAIT cells into Mr1 -/- mice reversed metastasis reduction. Similarly, MR1-blocking antibodies decreased lung metastases and suppressed tumor growth. Following MR1 ligand exposure, some, but not all, mouse and human tumor cell lines upregulated MR1. Pretreatment of tumor cells with the stimulatory ligand 5-OP-RU or inhibitory ligand Ac-6-FP increased or decreased lung metastases, respectively. MR1-deleted tumors resulted in fewer metastases compared with parental tumor cells. MAIT cell suppression of NK-cell effector function was tumor-MR1-dependent and partially required IL17A. Our studies indicate that MAIT cells display tumor-promoting function by suppressing T and/or NK cells and that blocking MR1 may represent a new therapeutic strategy for cancer immunotherapy. SIGNIFICANCE: Contradicting the perception that MAIT cells kill tumor cells, here MAIT cells promoted tumor initiation, growth, and metastasis. MR1-expressing tumor cells activated MAIT cells to reduce NK-cell effector function, partly in a host IL17A-dependent manner. MR1-blocking antibodies reduced tumor metastases and growth, and may represent a new class of cancer therapeutics.This article is highlighted in the In This Issue feature, p. 1. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31826876     DOI: 10.1158/2159-8290.CD-19-0569

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  38 in total

Review 1.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

2.  Chemical Modulators of Mucosal Associated Invariant T Cells.

Authors:  Jeffrey Y W Mak; Ligong Liu; David P Fairlie
Journal:  Acc Chem Res       Date:  2021-08-20       Impact factor: 22.384

Review 3.  MAIT cells and their implication in human oral diseases.

Authors:  Qin Jiang; Fang Wang; Jing-Ya Yang; Gang Zhou
Journal:  Inflamm Res       Date:  2022-07-04       Impact factor: 6.986

Review 4.  Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells.

Authors:  Benjamin Ruf; Bernd Heinrich; Tim F Greten
Journal:  Cell Mol Immunol       Date:  2020-11-24       Impact factor: 11.530

Review 5.  Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age?

Authors:  Jiajie Hou; Michael Karin; Beicheng Sun
Journal:  Nat Rev Clin Oncol       Date:  2021-01-19       Impact factor: 66.675

6.  MAIT cells numbers and frequencies in patients with acute myeloid leukemia at diagnosis: association with cytogenetic profile and gene mutations.

Authors:  Francois Vergez; Emmanuel Treiner; Thibault Comont; Marie-Laure Nicolau-Travers; Sarah Bertoli; Christian Recher
Journal:  Cancer Immunol Immunother       Date:  2021-09-03       Impact factor: 6.968

Review 7.  An Unconventional View of T Cell Reconstitution After Allogeneic Hematopoietic Cell Transplantation.

Authors:  Hana Andrlová; Marcel R M van den Brink; Kate A Markey
Journal:  Front Oncol       Date:  2021-02-18       Impact factor: 6.244

8.  Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.

Authors:  Yaqi Zhao; Ibrahim Aldoss; Chunxu Qu; Jeremy Chase Crawford; Zhaohui Gu; Emma K Allen; Anthony E Zamora; Thomas B Alexander; Jeremy Wang; Hiroaki Goto; Toshihiko Imamura; Koshi Akahane; Guido Marcucci; Anthony S Stein; Ravi Bhatia; Paul G Thomas; Stephen J Forman; Charles G Mullighan; Kathryn G Roberts
Journal:  Blood       Date:  2021-01-28       Impact factor: 22.113

Review 9.  Mouse models illuminate MAIT cell biology.

Authors:  Huimeng Wang; Zhenjun Chen; James McCluskey; Alexandra J Corbett
Journal:  Mol Immunol       Date:  2020-12-22       Impact factor: 4.407

Review 10.  MAIT Cells and Microbiota in Multiple Sclerosis and Other Autoimmune Diseases.

Authors:  Rosella Mechelli; Silvia Romano; Carmela Romano; Emanuele Morena; Maria Chiara Buscarinu; Rachele Bigi; Gianmarco Bellucci; Roberta Reniè; Giulia Pellicciari; Marco Salvetti; Giovanni Ristori
Journal:  Microorganisms       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.